BLCM Bellicum Pharmaceuticals Inc.

3.15
-0.02  -1%
Previous Close 3.17
Open 3.18
Price To Book 1.48
Market Cap 136587651
Shares 43,361,159
Volume 125,891
Short Ratio
Av. Daily Volume 454,494

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted 91% event-free survival (EFS) rate at 180 days at ASH December 2018. Final data 2019.
BPX-501
Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer
Phase 1 initial data released December 14, 2018 at ESMO noted 2/6 patients had tumor shrinkage >20%.
BPX-601
Pancreatic cancer
Phase 1/2 commenced March 2017. Initial data 2019.
BPX-701
PRAME (preferentially-expressed antigen in melanoma) -expressing melanoma, sarcomas and neuroblastoma cancer
Phase 2/3 trial to be initiated late-2018/ early-2019.
Rivo-cel
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)

Latest News

  1. Report: Developing Opportunities within Waste Connections, Performance Food Group, HealthEquity, PS Business Parks, Adverum Biotechnologies, and Bellicum Pharmaceuticals — Future Expectations, Projections Moving into 2019
  2. How Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Could Add Value To Your Portfolio
  3. Aratana Therapeutics (PETX) in Focus: Stock Moves 6.8% Higher
  4. Bellicum Pharmaceuticals Enters Oversold Territory
  5. Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA
  6. Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors
  7. Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO
  8. Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer
  9. Novan Announces Top-Line Data From Mid-Stage Molluscum Study
  10. Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel
  11. Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant
  12. Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018
  13. Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
  14. Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3
  15. Before You Buy Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), Consider Its Volatility
  16. Bellicum Pharmaceuticals (BLCM) Reports Q3 Loss, Tops Revenue Estimates